“This report is highly regarded in the industry. I sit on one of the IMC operational committees, where we often discuss access to therapies. In speaking with a colleague from [MFR], he mentioned that his company also purchases the CRaFT report. Lately, I have referenced the CRaFT report to help support discussions on access to drugs in certain provinces.”